The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
Open accessAbstract
Cholesteryl ester transfer protein (CETP) facilitates exchange of triglycerides and cholesteryl ester between high-density lipoprotein (HDL) and apolipoprotein B100-containing lipoproteins. Evidence from genetic studies that variants in the CETP gene were associated with higher blood HDL cholesterol, lower low-density lipoprotein cholesterol, and lower risk of coronary heart disease suggested that pharmacological inhibition of CETP may be beneficial. To date, 4 CETP inhibitors have entered phase 3 cardiovascular outcome trials. Torcetrapib was withdrawn due to unanticipated off-target effects that increased risk of death, and major trials of dalcetrapib and evacetrapib were terminated early for futility. In the 30,000-patient REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification) trial, anacetrapib doubled HDL cholesterol, reduced non-HDL cholesterol by 17 mg/dl (0.44 mmol/l), and reduced major vascular events by 9% over 4 years, but anaceptrapib was found to accumulate in adipose tissue, and regulatory approval is not being sought. Therefore, despite considerable initial promise, CETP inhibition provides insufficient cardiovascular benefit for routine use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 2×
“PCSK9 inhibitor Evolocumab (44) Subcutaneous in every 2–4”
BackgroundEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Cited by
Sorted by citations
HDL and Reverse Cholesterol Transport
Ouimet, M. I., Barrett, T. J., & Fisher, E. A. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.312617 · Cited by 816
Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations
Astrup, A. V., Magkos, F., Bier, D. M., Brenna, J. T., Otto, M. C. D. O., Hill, J. O., King, J. C., Mente, A., Ordovás, J. M., Volek, J. S., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.077 · Cited by 581
Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond
Fuior, E. V., & Gafencu, A. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235939 · Cited by 186
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Self-citationAdvances in HDL: Much More than Lipid Transporters
Ben‐Aicha, S., Badimón, L., & Vilahur, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030732 · Cited by 158
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
Schmidt, A. F., Hunt, N. B., Gordillo‐Marañón, M., Charoen, P., Drenos, F., Casas, J. P., Mika Kivimaki, B., Lawlor, D. A., Giambartolomei, C., Papacosta, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25703-3 · Cited by 142
Nazir, S., Jankowski, V., Bender, G., Zewinger, S., Rye, K.-A., & van der Vorst, E. P. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.006 · Cited by 140
Kris‐Etherton, P. M., & Krauss, R. M. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa110 · Cited by 145
Small molecules in the treatment of COVID-19
Lei, S., Chen, X., Wu, J., Duan, X., & Men, K. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01249-8 · Cited by 119
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 116
Rouland, A., Masson, D., Lagrost, L., Vergès, B. L., Gautier, T., & Bouillet, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01703-5 · Cited by 106
Nurmohamed, N. S., Ditmarsch, M., & Kastelein, J. J. P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab350 · Cited by 99
Georgakis, M. K., Malik, R., Anderson, C. D., Parhofer, K. G., Hopewell, J. C., & Dichgans, M. (2019) · Brain · doi:10.1093/brain/awz413 · Cited by 91
Kachuri, L., Mak, A. C. Y., Hu, D., Eng, C. S., Huntsman, S., Elhawary, J. R., Gupta, N., Gabriel, S., Xiao, S., Keys, K. L., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01377-z · Cited by 94
Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314050 · Cited by 88
Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83
Existing and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 86
High-Density Lipoproteins Are Bug Scavengers
Meilhac, O., Tanaka, S., & Couret, D. (2020) · Biomolecules · doi:10.3390/biom10040598 · Cited by 80
Nelson, A. J., Sniderman, A. D., Ditmarsch, M., Dicklin, M. R., Nicholls, S. J., Davidson, M. H., & Kastelein, J. J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169417 · Cited by 72
The Genetic Basis of Childhood Obesity: A Systematic Review
Vourdoumpa, A., Paltoglou, G., & Charmandari, E. (2023) · Nutrients · doi:10.3390/nu15061416 · Cited by 84
Nordestgaard, L. T., Christoffersen, M., Lauridsen, B. K., Afzal, S., Nordestgaard, B. G., Frikke‐Schmidt, R., & Tybjærg‐Hansen, A. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3728 · Cited by 64
Alcohol use and cardiometabolic risk in the UK Biobank: A Mendelian randomization study
Lankester, J., Zanetti, D., Ingelsson, E., & Assimes, T. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255801 · Cited by 56
Duparc, T., Ruidavets, J., Genoux, A., Ingueneau, C., Najib, S., Ferrières, J., Perret, B., & Martinez, L. O. (2020) · Scientific Reports · doi:10.1038/s41598-020-65100-2 · Cited by 54
Public health guidelines should recommend reducing saturated fat consumption as much as possible: NO
Krauss, R. M., & Kris‐Etherton, P. M. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa111 · Cited by 54
Taheri, H., Filion, K. B., Windle, S. B., Reynier, P., & Eisenberg, M. J. (2020) · Cardiology · doi:10.1159/000505365 · Cited by 54
Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 48
Treatment of Dyslipidaemia in Children
Fiorentino, R., & Chiarelli, F. (2021) · Biomedicines · doi:10.3390/biomedicines9091078 · Cited by 46
Cohen, H., Stefanutti, C., Giacomo, S. D., Morozzi, C., Widhalm, K., Bjelakovic, B. B., Berni, A., Martino, F., & Bosco, G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00926-3 · Cited by 44
High-Density Lipoprotein (HDL) in Allergy and Skin Diseases: Focus on Immunomodulating Functions
Trakaki, A., & Marsche, G. (2020) · Biomedicines · doi:10.3390/biomedicines8120558 · Cited by 39
Zuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 38
Structure-based mechanism and inhibition of cholesteryl ester transfer protein
Han, X. M., Zhang, M., Liu, J., Wang, J., & Ren, G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01087-1 · Cited by 37
Recent advances in synthetic pharmacotherapies for dyslipidaemias
Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34
Harsløf, M., Pedersen, K. M., Afzal, S., Smith, G. D., & Nordestgaard, B. G. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac194 · Cited by 31
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 36
High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important?
Lappegård, K. T., Kjellmo, C. A., & Hovland, A. (2021) · Biomedicines · doi:10.3390/biomedicines9070836 · Cited by 30
High-Density Lipoproteins as Homeostatic Nanoparticles of Blood Plasma
Kudinov, V. A., Alekseeva, O. Y., Torkhovskaya, T. I., Baskaev, K. K., Artyushev, R. I., Saburina, I. N., & Markin, S. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228737 · Cited by 29
Wanschel, A. C. B. A., Guizoni, D. M., Lorza‐Gil, E., Salerno, A. G., Paiva, A. A., Dorighello, G. G., Davel, A. P., Balkan, W., Hare, J. M., & Oliveira, H. C. F. (2021) · Biomolecules · doi:10.3390/biom11010069 · Cited by 28
Low High-Density Lipoprotein Cholesterol and High White Blood Cell Counts
Harsløf, M., Pedersen, K. M., Nordestgaard, B. G., & Afzal, S. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314983 · Cited by 27
Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives
Karantas, I. D., Okur, M. E., Okur, N. Ü., & Siafaka, P. I. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200810144004 · Cited by 25
New algorithms for treating homozygous familial hypercholesterolemia
Tromp, T. R., & Cuchel, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000853 · Cited by 25
Rehman, W. U., Yarkoni, M., Ilyas, M. A., Athar, F., Javaid, M., Ehsan, M. T., Khalid, M. T., Pasha, A. K., Selma, A. B., Yarkoni, A., et al. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050152 · Cited by 26
Banerjee, S., & De, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.016 · Cited by 22
Tufaro, V., Serruys, P. W. J. C., Räber, L., Bennett, M. R., Torii, R., Gu, S. Z., Onuma, Y., Mathur, A., Baumbach, A., & Bourantas, C. V. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac051 · Cited by 22
Kounatidis, D. C., Tentolouris, N., Vallianou, N. G., Mourouzis, I. S., Karampela, Ι., Stratigou, T., Rebelos, E., Kouveletsou, M., Stamatopoulos, V., Tsaroucha, E., et al. (2024) · Metabolites · doi:10.3390/metabo14070388 · Cited by 23
Anti-atherosclerotic effects of an improved apolipoprotein A-I mimetic peptide
Suematsu, Y., Kawachi, E., Idemoto, Y., Matsuo, Y., Kuwano, T., Kitajima, K., Imaizumi, S., Kawamura, A., Saku, K., Uehara, Y., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.08.043 · Cited by 21
Zhu, X.-T., Liu, X., Liu, Y. M., Chang, W., Song, Y., & Zhu, S. (2020) · European Neurology · doi:10.1159/000507364 · Cited by 20
Pan, B.-Y., Chen, C.-S., Chen, F.-Y., & Shen, M.-Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312759 · Cited by 19
Vania, V., Wang, L., Tjakra, M., Zhang, T., Qiu, J., Tan, Y., & Wang, G. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165645 · Cited by 21
Schooling, C. M., & Ng, J. C. M. (2019) · SSM - Population Health · doi:10.1016/j.ssmph.2019.100411 · Cited by 19
Liu, G., Jiang, L., Kerchberger, V. E., Oeser, A. M., Ihegword, A., Dickson, A. L., Daniel, L. L., Shaffer, C. M., Linton, M. F., Cox, N. J., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13462 · Cited by 18
In vivo evaluation of the anti-obesity effects of combinations of Monascus pigment derivatives
Choe, D., Jung, H. H., Kim, D., Shin, C. S., Johnston, T. V., & Ku, S. (2020) · RSC Advances · doi:10.1039/c9ra08036h · Cited by 18
Parada-Turska, J., Wójcicka, G., & Bełtowski, J. (2020) · Antioxidants · doi:10.3390/antiox9090899 · Cited by 18
Wilkens, T. L., Tranæs, K., Eriksen, J. N., & Dragsted, L. O. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuab102 · Cited by 18
Patel, P. N., & Giugliano, R. P. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.39 · Cited by 19
Liu, D., Zhang, Y. P., Wang, C., & Zuo, H. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.033 · Cited by 14
Aguchem, R. N., Okagu, I. U., Okorigwe, E. M., Uzoechina, J. O., Nnemolisa, S. C., & Ezeorba, T. P. C. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122823 · Cited by 17
Bilgic, S., Pencina, K. M., Pencina, M. J., Cole, J., Dufresne, L., Thanassoulis, G., & Sniderman, A. D. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321165 · Cited by 15
Cholesteryl ester transfer protein inhibitors in precision medicine
Su, X., Li, G., Deng, Y., & Chang, D. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.09.012 · Cited by 14
Bergougnan, L., Andersen, G., Plum‐Mörschel, L., Evaristi, M. F., Poirier, B., Tardat, A., Ermer, M., Herbrand, T., Arrubla, J., Coester, H. V., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14632 · Cited by 14
Orsi, E., Penno, G., Solini, A., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Morano, S., Baroni, M. G., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01224-7 · Cited by 14
Xu, Y., Li, F., Zhao, X., Tan, C., Wang, B., Chen, Y., Cao, J., Wu, D., & Yu, H. (2020) · The FASEB Journal · doi:10.1096/fj.201902429r · Cited by 13
Genetic Variants behind Cardiovascular Diseases and Dementia
Ho, W.-M., Wu, Y.-Y., & Chen, Y. (2020) · Genes · doi:10.3390/genes11121514 · Cited by 13
Colombo, G. I., Bianconi, V., Bonomi, A., Simonelli, S., Amato, M., Frigerio, B., Ravani, A. L., Vitali, C., Sansaro, D., Coggi, D., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9030286 · Cited by 12
Kaur, M., Ahuja, K. R., Khubber, S., Zhou, L., Verma, B. R., Meenakshisundaram, C., Gad, M. M., Saad, A. M., Dhaliwal, K., Isogai, T., et al. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.01.014 · Cited by 12
Visioli, F., Martínez‐Urbistondo, D., Gkipalis, S., Lara, F. V.-O. D., Ruiz-Saavedra, A., Leon, M., Chaib, F. B., Hernández, A., Landecho, M. F., Laparra, M., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104215 · Cited by 16
Lee, C.-C., Hung, C., Chen, C., Hsu, Y., Huang, Y.-P., Huang, T., & Lee, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158320 · Cited by 11
Uehara, Y., Komatsu, T., Sasaki, K., Abe, S., Nakashima, S., Yamamoto, T., Kim, J. E., & Cho, K. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1297008 · Cited by 11
Li, W., Liu, X., Huang, C., Liu, L., Tan, X., & Wang, X. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.10.019 · Cited by 12
Scavenger Receptor BI Induced by HDL From Coronary Heart Disease May Be Related to Atherosclerosis
Fen, G., Feng, G.-J., Li, H., Qin, W.-W., & Chuan-shi, X. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211029710 · Cited by 10
Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention
Hu, W., Han, F., Liu, Y., Xu, X., Zhou, P., Sun, Z., Tao, X., Yang, J., Wu, J., Qu, C., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2462466 · Cited by 10
Liang, Y.-Q., Isono, M., Okamura, T., Takeuchi, F., & Kato, N. (2020) · Hypertension Research · doi:10.1038/s41440-020-0401-9 · Cited by 11
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 9
A latent mixture model for heterogeneous causal mechanisms in Mendelian randomization
Iong, D., Zhao, Q., & Chen, Y. (2024) · The Annals of Applied Statistics · doi:10.1214/23-aoas1816 · Cited by 11
A Novel Indicator for HDL Functionality
Irino, Y., Toh, R., & Ishida, T. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed111 · Cited by 8
Asparagine endopeptidase cleaves apolipoprotein A1 and accelerates pathogenesis of atherosclerosis
Wang, M., Li, B., Nie, S., Meng, X., Wang, G., Yang, M., Dang, W., He, K., Sun, T., Xu, P., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci185128 · Cited by 7
Ronca, A., Pellegrini, N., Pagliai, G., Dinu, M., Manfredini, M., Incerti, M., Favari, E., & Sofi, F. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.11.012 · Cited by 7
Noflatscher, M., Hunjadi, M., Schreinlechner, M., Sommer, P., Lener, D., Theurl, M., Kirchmair, R., Bauer, A., Ritsch, A., & Marschang, P. (2023) · Biomedicines · doi:10.3390/biomedicines11071918 · Cited by 7
Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment
Arnold, N., & Köenig, W. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2408236 · Cited by 11
Shirolkar, A. R., Yadav, A., Nale, A., Phogat, J., & Dabur, R. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-00985-6 · Cited by 6
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 9
Lower LDL is better – can this be achieved with CETP inhibition therapy?
Rashid, S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1715797 · Cited by 7
Plasma Biomarker Profiles for Premature and Nonpremature Coronary Heart Disease in Women
Dugani, S. B., Moorthy, M. V., Demler, O., Li, C., Ridker, P. M., Glynn, R. J., & Mora, S. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae007 · Cited by 6
Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?
Grabie, M., Tai, C.-H., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000245 · Cited by 6
Ueland, T., Roland, M. C. P., Michelsen, A. E., Godang, K., Aukrust, P., Henriksen, T., Bollerslev, J., & Lekva, T. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz119 · Cited by 6
PCSK9 inhibition, LDL and lipopolysaccharides: a complex and "dangerous" relationship
Feminò, R., Feminò, G., Cavezzi, A., & Troiani, E. (2021) · International Angiology · doi:10.23736/s0392-9590.21.04632-0 · Cited by 6
Kachuri, L., Mak, A. C. Y., Hu, D., Eng, C. S., Huntsman, S., Elhawary, J. R., Gupta, N., Gabriel, S., Xiao, S., Keys, K. L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.19.456901 · Cited by 6
Kawahira, Y., Shiga, Y., Inoue, H., Suematsu, Y., Tashiro, K., Kato, Y., Fujimi, K., Takamiya, Y., Kuwano, T., Sugihara, M., et al. (2021) · Heart and Vessels · doi:10.1007/s00380-021-01831-0 · Cited by 5
Dysregulated Lipid Metabolism as a Central Driver of Atherosclerotic Plaque Pathology
Steinbeck, J. E., Iannotti, R. A., & Rasheed, A. (2025) · Lipidology · doi:10.3390/lipidology2040017 · Cited by 5
Wei, S., Fu, W.-S., Liu, C.-H., Wang, W.-L., Shih, Y., Chien, S., & Chiu, J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318718121 · Cited by 4
Mapping drug biology to disease genetics to discover drug impacts on the human phenome
Habib, M., Lalagkas, P. N., & Melamed, R. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbae038 · Cited by 4
Khalaf, R. A., Lafi, A., Hajjo, R., & Al-Sha’er, M. A. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099292078240218095540 · Cited by 3
The Role of Genetics in Advancing Cardiometabolic Drug Development
Abou-Karam, R., Cheng, F., Gady, S., & Fahed, A. C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01195-6 · Cited by 3
Long, J., Xue, Y., Xiaorong, Z., Dan, L., Ma, Y., Jiahuan, R., Bin, Z., Li, L., & Zhigang, G. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02354-2 · Cited by 3
Tashiro, K., Inoue, H., Shiga, Y., Tsukihashi, Y., Imaizumi, T., Norimatsu, K., Idemoto, Y., Kuwano, T., Sugihara, M., Nishikawa, H., et al. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4367 · Cited by 4
Weiss, M., Fellmann, L., Régnard, P., Bousquet, P., Monassier, L., & Niederhoffer, N. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00786-6 · Cited by 3
Darabi, M., Zakiev, E., & Kontush, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_18 · Cited by 3
The two faces of cholesteryl ester transfer protein inhibitors
Pirillo, A., & Catapano, A. L. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001017 · Cited by 2
Arun, A. J., Kaneki, S., Baig, M., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001126 · Cited by 3
Prajapathi, S., Mahajan, K., Mohta, A., & Pradhan, A. K. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047676 · Cited by 3
Metadata
- Authors
- Armitage, J., Holmes, M. V., & Preiss, D.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Armitage, Jane
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 73
- Issue
- 4
- Pages
- 477-487
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC6354546
- OpenAlex
- W2911625798
- Cited by
- 140
- References
- 46
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 19 · 2023: 11 · 2022: 15 · 2021: 30 · 2020: 28 · 2019: 17
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute for Health and Care Research
- British Heart Foundation (18/23/33512, RE/13/1/30181, FS/18/23/33512)
- University of Oxford (RE/13/1/30181)
- Merck Sharp and Dohme
- Medical Research Council (13/1/30181, RE/13/1/30181)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- cholesteryl ester transfer protein, CETP inhibitors, cardiovascular events, HDL cholesterol, anacetrapib, torcetrapib, dalcetrapib, evacetrapib, coronary artery disease, non-HDL cholesterol, cardiovascular outcome trials, drug safety, adipose tissue accumulation
- MeSH terms
- Animals, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Clinical Trials, Phase III as Topic, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
